Journal of Clinical Oncology, Vol 10, 316-322, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

JA Talcott, RD Siegel, R Finberg and L Goldman
Dana-Farber Cancer Institute, Boston, MA 02115.

PURPOSE: The study was undertaken to validate a clinical model for predicting the medical risk of cancer patients with fever and neutropenia. PATIENTS AND METHODS: A consecutive sample of 444 cancer patients with fever and neutropenia (granulocyte count less than 500/microL) at two hospitals, a specialized cancer referral center and a university-affiliated general medical hospital, was studied to identify clinical characteristics in the first 24 hours that predict subsequent serious medical complications during the hospital stay. To control for bias, major risk factors and complications were subject to blinded review. RESULTS: Serious medical complications occurred in 34% of patients with risk factors identified in a prior study, including prior inpatient status (group I), outpatients with a serious independent comorbidity (group II), or uncontrolled cancer (group III), compared with 5% of the remaining patients (group IV) (P less than .000001). Two of the complications in group IV patients were transient asymptomatic hypotension, and the remaining three complications occurred after at least 1 week of progressive medical deterioration. These risk groups were independently significant in stepwise logistic regression analysis. Multiple complications (17%) and death (10%) were common among patients in groups I through III but did not occur in group IV patients. CONCLUSIONS: This risk assessment model accurately stratified the medical risk of these patients using only clinical information available on the first day of their course. Low-risk patients are an appropriate population in which to study less intensive treatment strategies.

This article has been cited by other articles:

				E. G. C. Brain, T. Bachelot, D. Serin, S. Kirscher, Y. Graic, J.-C. Eymard, J.-M. Extra, M. Combe, E. Fourme, C. Nogues, et al. Life-Threatening Sepsis Associated With Adjuvant Doxorubicin Plus Docetaxel for Intermediate-Risk Breast Cancer JAMA, May 18, 2005; 293(19): 2367 - 2371. [Abstract] [Full Text] [PDF]

				L. Vidal, M. Paul, I. Ben dor, K. Soares-Weiser, and L. Leibovici Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials J. Antimicrob. Chemother., July 1, 2004; 54(1): 29 - 37. [Abstract] [Full Text] [PDF]

				A. Gassas, R. Grant, S. Richardson, L. L. Dupuis, J. Doyle, U. Allen, O. Abla, and L. Sung Predictors of Viridans Streptococcal Shock Syndrome in Bacteremic Children With Cancer and Stem-Cell Transplant Recipients J. Clin. Oncol., April 1, 2004; 22(7): 1222 - 1227. [Abstract] [Full Text] [PDF]

				S. Niho, Y. Ohe, K. Goto, H. Ohmatsu, T. Matsumoto, K. Kubota, R. Kakinuma, and Y. Nishiwaki Randomized Trial of Oral Versus Intravenous Antibiotics in Low-risk Febrile Neutropenic Patients with Lung Cancer Jpn. J. Clin. Oncol., February 1, 2004; 34(2): 69 - 73. [Abstract] [Full Text] [PDF]

				M. E. Santolaya, A. M. Alvarez, A. Becker, J. Cofre, N. Enriquez, M. O'Ryan, E. Paya, J. Pilorget, C. Salgado, J. Tordecilla, et al. Prospective, Multicenter Evaluation of Risk Factors Associated With Invasive Bacterial Infection in Children With Cancer, Neutropenia, and Fever J. Clin. Oncol., July 15, 2001; 19(14): 3415 - 3421. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero, J. I. Mayordomo, M. V. Tornamira, M. Lopez-Brea, A. Rueda, V. Guillem, A. Arcediano, A. Yubero, F. Ribera, C. Gomez, et al. Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial J Natl Cancer Inst, January 3, 2001; 93(1): 31 - 38. [Abstract] [Full Text] [PDF]

				L. S. Elting, E. B. Rubenstein, K. Rolston, S. B. Cantor, C. G. Martin, D. Kurtin, S. Rodriguez, T. Lam, K. Kanesan, and G. Bodey Time to Clinical Response: An Outcome of Antibiotic Therapy of Febrile Neutropenia With Implications for Quality and Cost of Care J. Clin. Oncol., November 1, 2000; 18(21): 3699 - 3706. [Abstract] [Full Text] [PDF]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				J. Klastersky, M. Paesmans, E. B. Rubenstein, M. Boyer, L. Elting, R. Feld, J. Gallagher, J. Herrstedt, B. Rapoport, K. Rolston, et al. The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients J. Clin. Oncol., August 16, 2000; 18(16): 3038 - 3051. [Abstract] [Full Text] [PDF]

				E. Blot, F. Heron, M. Lishner, E. B. Rubenstein, K. V.I. Rolston, Y. J. Kim, O. Sezer, A. G. Freifeld, S. M. Steinberg, P. A. Pizzo, et al. Oral Antibiotics for Febrile Patients with Neutropenia Due to Cancer Chemotherapy N. Engl. J. Med., January 6, 2000; 342(1): 55 - 58. [Full Text]

				A. Freifeld, D. Marchigiani, T. Walsh, S. Chanock, L. Lewis, J. Hiemenz, S. Hiemenz, J. E. Hicks, V. Gill, S. M. Steinberg, et al. A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer Chemotherapy N. Engl. J. Med., July 29, 1999; 341(5): 305 - 311. [Abstract] [Full Text] [PDF]

				W. V. Kern, A. Cometta, R. de Bock, J. Langenaeken, M. Paesmans, H. Gaya, G. Zanetti, T. Calandra, M. P. Glauser, F. Crokaert, et al. Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy N. Engl. J. Med., July 29, 1999; 341(5): 312 - 318. [Abstract] [Full Text] [PDF]

				R. W. Finberg and J. A. Talcott Fever and Neutropenia -- How to Use a New Treatment Strategy N. Engl. J. Med., July 29, 1999; 341(5): 362 - 363. [Full Text]

				O. Uzun and E. J. Anaissie Outpatient therapy for febrile neutropenia: who, when and how? J. Antimicrob. Chemother., March 1, 1999; 43(3): 317 - 320. [Full Text] [PDF]

				J. A. Talcott Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care? Oncologist, December 1, 1997; 2(6): 365 - 373. [Abstract] [Full Text] [PDF]

				B. R. Paschal, J. D. Gradon, K. V.I. Rolston, E. B. Rubenstein, and P. A. Pizzo Fever in Patients with Neutropenia N. Engl. J. Med., October 21, 1993; 329(17): 1279 - 1280. [Full Text]

				P. A. Pizzo Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia N. Engl. J. Med., May 6, 1993; 328(18): 1323 - 1332. [Full Text]